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AcyclovirIntravenous immunoglobulin (IVIG) treatment of Alzheimer's disease (AD) has been encouraging. Its mech-
anism of action might be via anti-β-amyloid (Aβ) antibodies which facilitate Aβ clearance. However, IVIG's
beneﬁts might result from its antiviral activity, particularly against herpes simplex virus type 1 (HSV1), a
virus implicated in AD. We investigated IVIG's effect on HSV1, speciﬁcally on the accumulation of Aβ and ab-
normally phosphorylated tau which it causes. We show that IVIG is effective at reducing the accumulation of
these abnormal molecules and that it acts synergistically with the antiviral acyclovir, suggesting that their
combined use would be beneﬁcial for treating AD.
© 2013 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Intravenous immunoglobulin (IVIG) is a therapeutic product de-
rived from the pooled plasma of thousands of people. It is used to
treat immune-deﬁcient patients who have reduced antibody levels.
IVIG has also been tried as a treatment for Alzheimer's disease (AD)
(Devi et al., 2008; Fillit et al., 2009; Relkin et al., 2009), the rationale
being that it contains antibodies against the toxic protein β-amyloid
(Aβ), the main component of amyloid plaques, which are a hallmark
feature of AD. IVIG is thus thought to augment the presumed rela-
tively low level of the patients' Aβ antibodies, thereby enhancing
Aβ clearance. However, although treatment led to some encouraging
preliminary effects on cognitive function (Devi et al., 2008; Relkin et
al., 2009), the usage of monoclonal anti-Aβ antibodies for treatment
has not yet done so. One explanation is that the treatment was given
at too late a stage in the disease (therefore to investigate this, new
trials are being set up which will initiate treatment at a much earlier
stage). Alternatively, in the positive preliminary studies, IVIG might
have affected some factor other than Aβ, perhaps through its
antiviral properties. IVIG contains large amounts of neutralising an-
tibodies to many microbes and so in AD patients it might have
inhibited the action of an infectious agent.
Herpes simplex virus type 1 (HSV1), amicrobe against which IVIG is
known to have antiviral action (Erlich and Mills, 1986; Kohl and Loo,, Faculty of Life Sciences, The
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Itzhaki).
-NC-ND license.1986; Masci et al., 1995), has been implicated as a cause of AD. The
ﬁrst relevant ﬁnding was our discovery that HSV1 DNA is present in a
high proportion of AD patients and aged normals (Jamieson et al.,
1991, 1992) and that when in brain of APOE-ε4 carriers it confers a
strong risk for AD (Itzhaki et al., 1997; Lin et al., 1998). Later, we
detected intrathecal antibodies to HSV in aged normals and AD patients
(Wozniak et al., 2005), conﬁrming HSV1 presence in brain and indicat-
ing that the virus had been actively replicating— and hence likely caus-
ing damage.We then found that HSV1-infection of cultured neural cells
causes a large increase in Aβ, and that Aβ deposition occurs in brains of
HSV1-infectedmice (Wozniak et al., 2007); also, in HSV1-infected neu-
ral cell cultures, abnormally phosphorylated tau (P-tau), themain com-
ponent of neuroﬁbrillary tangles, is formed (Wozniak et al., 2009a).
Recent data by others support these results in showing similar effects
of HSV1 onAβ and P-tau (see (Alvarez et al., 2012) and referenceswith-
in (Wozniak et al., 2011)). A further major discovery was that in AD
brains, HSV1 DNA localises very speciﬁcally to amyloid plaques
(Wozniak et al., 2009b). The latter result, together with the fact that
HSV1 causes Aβ production, suggests that HSV1 is a major factor in
the formation of toxic Aβ products and amyloid plaques.
These data point to the use of antiviral agents to stop the progres-
sion of AD. Themain antiviral agent used to combat HSV1 is acyclovir
(ACV); however, antivirals such as ACV that target HSV1 DNA repli-
cation might be successful only if Aβ and P-tau accumulations de-
pend on viral DNA replication, prompting us to investigate ACV
effects on Aβ and P-tau in HSV1-infected cells. We found that P-tau
accumulation does depend on HSV1 DNA replication whereas Aβ ac-
cumulation does not, but treatment of HSV1-infected cell cultures
with ACV greatly reduces both products (Wozniak et al., 2011),
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production of new viruses and hence decreased viral spread. However,
ACVdid not reduceAβ to control levels, suggesting that antiviralswhich
act prior to viral DNA replication might be preferable for treating AD.
IVIG is a possibility as it can neutralise extracellular virus and also
help (in conjunctionwith lymphocytes) to destroy cells acutely infected
with HSV1 (Kohl and Loo, 1986) — a useful feature as the virus can be
transferred from cell to cell without the release of extracellular virus.
In the present preliminary study we therefore aimed to ﬁnd if IVIG re-
duces the production of Aβ and of P-tau, to compare any such reduc-
tions with those produced by ACV, and to ﬁnd the combined effect of
the two agents, using infected cell cultures.2. Methods
2.1. Viruses, cells and antiviral agents
We used HSV1 strain SC16 prepared as previously described
(Dobson et al., 2006). African Green Monkey kidney (Vero) cells
were cultured as previously described (Wozniak et al., 2011). ACV
was purchased from Sigma-Aldrich and IVIG (Privigen) was provid-
ed by CSL Behring.
Vero cells were cultured into wells of 24-well plates at 80%
conﬂuency and left overnight to settle. HSV1 infection was carried
out either at a dose of 20 plaque-forming units (pfu/cell), incubating
the cells for 7 h, or at a dose of 0.01 pfu/cell, incubating for 23 h. ACV
or Privigen, or in the case of the low dose, long incubation experi-
ments, ACV and Privigen together, were added concurrently with
the virus suspension. After the incubation, the cells were ﬁxed in
PBS containing 4% formaldehyde and 10% acetic acid.Fig. 1. The effect of Privigen (and acyclovir) on HSV1 proteins, β-amyloid and abnormal tau ph
(20 pfu/cell) for 7 h, which allowed only 1 cycle of viral replication to occur. Cells were treated
or were untreated; the antivirals were present throughout infection. After ﬁxation the cells w
(AT100) using immunocytochemistry. Scale bars: 50 μm.2.2. Immunocytochemistry
Cells were washed twice in Tris-buffered saline (TBS) for 5 min and
then twice in TBS containing 0.025% Triton X-100 (TBS-Tx) (each wash
lasting 5 min), before being blocked for 1 h at room temperature in TBS
containing 10% goat serum. After two ﬁve-minute washes in TBS-Tx,
primary antibody was applied. Slides were incubated overnight at
4 °C, washed in TBS-Tx and biotinylated secondary antibody was
added for 1 h. Subsequently, the slides were washed in TBS-Tx and
then treated with an extravidin–alkaline phosphatase conjugate for
30 min before being washed in TBS. Substrate (BCIP/NBT) was then
added until sufﬁcient staining had developed. The primary and second-
ary antibodies have been described previously (Wozniak et al., 2011).
2.3. Quantiﬁcation of results
We quantiﬁed the ICC staining using the image analysis software
Image J, which we previously validated for HSV1 using standard viro-
logical methods— HSV1 ELISA and plaque reduction assays (Wozniak
et al., 2011). For each antibody we analysed three ﬁelds of view, mea-
suring the total staining in the ﬁeld. With Aβ, presence of Privigen
resulted in background staining; to compensate for the latter, values
obtained for mock-infected cells were subtracted.
To examine the effects on viral spread, we used low HSV1 doses
for relatively long duration; this resulted in the formation of clusters
of cells of size up to a few hundred cells per area. To assess the effect
of ACV and Privigen on the numbers of cluster, numbers were count-
ed in four ﬁelds of view, and the average number was determined.
Student's T-test was used to determine statistically signiﬁcant differ-
ences between the quantitative ICC values. Student's T-test was used
also to determine difference in the number of clusters. In each case,osphorylation (high HSV1 dose, short duration). Vero cells were infected with HSV1 SC16
eitherwith 0.4 mg/ml acyclovir (ACV), or with 0.4 mg/ml, 5 mg/ml or 10 mg/ml Privigen,
ere tested for HSV1 proteins, β-amyloid accumulation and abnormal tau phosphorylation
Fig. 2. The effect of Privigen (and acyclovir) on levels of HSV1 proteins, β-amyloid and
abnormal tau phosphorylation. Vero cells were infected with HSV1 SC16 (20 pfu/cell)
for 7 h, which allowed only 1 cycle of viral replication to occur. Cells were treated ei-
ther with 0.4 mg/ml acyclovir (ACV), or with 0.4 mg/ml, 5 mg/ml or 10 mg/ml
Privigen, or were untreated; the antivirals were present throughout infection. After ﬁx-
ation the cells were tested for (A) HSV1 proteins, (B) β-amyloid (Aβ) accumulation
and (C) abnormal tau phosphorylation (AT100) using immunocytochemistry, and the
amount of staining was quantiﬁed using Image J. Values are expressed as a percentage
of staining produced when no antiviral was used. p-Values indicate statistical signiﬁ-
cance (using Student's T-test) of data for each antiviral treatment compared with no
antiviral treatment.
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antiviral treatment.
3. Results
3.1. Effects of Privigen during infection level and duration sufﬁcient for
1 cycle of HSV1 replication in all cells
Initial experiments were carried out using a sufﬁciently high dose of
HSV1 to ensure that every cell was infected on initial exposure to the
virus; this enabled the expected preventive action of Privigen on virus
entry to be detectable. We examined the effects of Privigen at 0.4, 5
and 10 mg/ml, but ACV only at 0.4 mg/ml (in aqueous solutions ACV
is not soluble at 5 and 10 mg/ml). Fig. 1 shows that Privigen greatly re-
duced levels of HSV1 proteins, Aβ and P-tau. At 5 and 10 mg/ml there
was a large reduction in HSV1, P-tau and Aβ, suggesting that Privigen
greatly reduced viral entry and hence production of Aβ and P-tau.
There was a modest effect with Privigen at 0.4 mg/ml. ACV had only a
modest effect on levels of all proteins, presumably because its concen-
tration was insufﬁcient to reduce viral DNA replication adequately.
Quantiﬁcation shows that at 0.4 mg/ml, ACV reduced HSV1 staining
by 52% (compared with the values obtained for HSV1-infected, no
antiviral), and Privigen, at the same w/v concentration, reduced the
staining by 58% (Fig. 2). For Aβ, ACV reduced staining by only 10%
whereas Privigen, at the same w/v concentration, reduced the staining
by 64%. For P-tau, ACV reduced staining by 20% whereas Privigen, at
the same w/v concentration, reduced the staining by 64%. Further,
higher concentrations of Privigen were much more effective, reducing
HSV1, Aβ and P-tau stainings to very low levels.
3.2. Effects of Privigen during infection level and duration appropriate for
cell-to-cell spread of HSV1
We investigated the effect of Privigen on the spread of HSV1 using
a low dose of HSV1 for a long duration. This allowed viral cell-to-cell
spread and caused clustering of infected cells, which were clearly vis-
ible when stained by immunocytochemistry for HSV1 proteins, Aβ
and P-tau (Fig. 3). All three types of staining showed that treatment
with ACV at 0.4 mg/ml reduced the size of clusters considerably
(resulting in most cases to a single cell), but not their number.
Privigen treatment did reduce cluster number — to zero at 5 mg/ml
and 10 mg/ml, and reduced cluster size slightly at 0.4 mg/ml (Fig. 3).
3.3. Effects of Privigen and ACV together during cell-to-cell spread of
HSV1
The combination of ACV and Privigen had little effect on the cluster
size compared with ACV alone (Fig. 4). Quantiﬁcation of the results re-
vealed that at 0.4 mg/ml, ACV reduced the staining of clusters for HSV1,
Aβ and P-tau by 93%, 71% and 84%, respectively (Fig. 5A). Privigen re-
duced staining by 90%, 10% and 26%, and the combination by 97%, 68%
and 84%, respectively. Analysis of the numbers of clusters (based on
HSV1 staining) (Fig. 5B) revealed that ACV had no effect on the actual
number of clusters but Privigen reduced their number as did the combi-
nation. In the case of Aβ and P-tau, ACV reduced the number of clusters
but the effect was greater with Privigen and with the combination.
These results show that the combination of Privigen and ACV reduces
both the number of clusters and the size of the clusters.
4. Discussion
Our ﬁrst main ﬁnding is that in HSV1-infected Vero cells, Privigen
causes statistically signiﬁcant reductions, particularly at higher concen-
trations, in levels of Aβ and P-tau, aswell as in HSV1 proteins. This prob-
ably results from Privigen preventing viral entry into cells; thus, few
viruses would enter the cells and few cells would be stained. ACVdoes not affect virus entry, so it would not affect numbers of infected
cells, but by inhibiting virus replication it would reduce subsequent
spread — accounting for the small cluster sizes and low staining.
Our second ﬁnding is that Privigen and ACV together act synergis-
tically, causing statistically signiﬁcant reductions in these levels, pre-
sumably resulting from the combination of prevention of viral entry
and inhibition of DNA replication of any virus that has evaded the
prevention. These data suggest that Privigen would be a suitable
antiviral agent for treating AD, and that its action would be even
more effective if used in combination with ACV.
IVIG is known to act against a number of infectious diseases. Its
mechanisms of action are believed to include neutralisation of patho-
gens and of their cell receptors (Bayry et al., 2004). It has been used
successfully to treat HSV1 diseases in animals and humans. In murine
Fig. 3. The effect of Privigen (and acyclovir) on HSV1 proteins, β-amyloid and abnormal tau phosphorylation (low HSV1 dose, long duration). Cells were infected with HSV1 SC16
(0.01 pfu/cell) for 23 h, which allowed cell-to-cell spread of the virus and resulted in clusters of infected cells. Cells were treated either with 0.4 mg/ml acyclovir (ACV), or with
0.4 mg/ml, 5 mg/ml, or 10 mg/ml Privigen, or were untreated; the antivirals were present throughout infection. After ﬁxation the cells were tested for HSV1 proteins,
β-amyloid accumulation and abnormal tau phosphorylation (AT100) using immunocytochemistry. Scale bars: 50 μm.
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cephalitis, IVIG protected the animals against death, and it reduced
the number of trigeminal ganglia containing latent HSV1 (Erlich and
Mills, 1986). Further, IVIG-treated genital herpes in humans (caused
by HSV1 as well as HSV2) reduced recurrence frequency and dura-
tion, and lesion severity more effectively than did ACV, and there
was a trend towards IVIG causing a greater reduction in viral load
(Masci et al., 1995) (also, most patients preferred the IVIG treatment
of one day per month compared to that of ACV twice per day for one
week each month.). We have proposed that HSV1 in brain reactivates
from latency, as it does in the peripheral nervous system, during
events such as stress and peripheral infections, and that it then causes
damage which is particularly severe in APOE-ε4 carriers, leading to
the development of AD. Therefore if IVIG reduces HSV1 reactivation
frequency and duration in the brain as it does in genital herpes, it
should be a particularly effective antiviral agent for treating AD.
Interestingly, a small scale retrospective study of AD patients
treated with IVIG for a few months found that it was well-tolerated,
and that neurocognitive test scores were either stable or else showed
trends towards improvement in some aspects (Devi et al., 2008). A
subsequent equally small study of IVIG-treated patients with mild
AD showed that anti-Aβ antibodies in serum increased proportion-
ately to IVIG dose, and that mini-mental state scores increased during
treatment (Relkin et al., 2009). A recent retrospective study found
that prior treatment with IVIG (at least once during a 3 year period)
reduced the risk of developing AD in patients aged 65 years or over,
compared with untreated controls, although over 30% of those treat-
ed with IVIG had cancer diagnoses, and so their lower risk of AD
might have reﬂected their associated treatments and diagnoses
(Fillit et al., 2009). It is unknown whether or not in these studies
there was an IVIG-induced anti-HSV1 action (especially in APOE-ε4
carriers, but unfortunately no data on APOE genotypes were given).However, an anti-HSV1 action might explain the apparent paradox
that monoclonal Aβ antibody treatment was not beneﬁcial (Relkin
et al., 2009). Our results suggest that at least in some patients —
those with HSV1 in brain and who were APOE-ε4 carriers, the protec-
tive effect of IVIG might have been mediated via its inhibitory action
on HSV1 and the consequent reduction in Aβ and P-tau.Acknowledgments
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